NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/10/2024
Back to search
Official data from USPTO
MOLECURE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
40
Latest update
12/10/2024
Trademark type
Combined
Nice classes
42
Filing date
12/20/2021
Registration date
12/10/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/10/2024
Last transaction
12/10/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2018-00-00
First use in commerce
2021-00-00
Drawing code
5
Owner type
03
Owner location
WARSZAWA POLAND, PL
Examiner
ZARICK, DIANA
Law office
N80
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "MOLECURE" in stylized font.
Holders and representatives
Holders
M. A. (pessoa física)
OncoArendi Therapeutics S.A.
Representatives
David Orms POLSON INTELLECTUAL PROPERTY LAW PC
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Medical and pharmacological research services; research and development services in the field of antibodies; research and development services in the field of immunology; research and development in the pharmaceutical and biotechnology fields; drug discovery services; development of pharmaceutical preparations and medicines; research on the subject of pharmaceuticals; conducting clinical trials for others for pharmaceutical products; biological researchclinical research in the field of inflammatory diseases and diseases leading to tissue fibrosisimmunology and cancermedical research; medical laboratory services; scientific laboratory services; analysis of human tissues for medical research; laboratory serviceslaboratory research servicesmedical laboratory servicesscientific laboratory services relating to the production of monoclonal antibodies; medical research and scientific analysis in the field of immunology and antibodies; scientific research for medical purposes in the area of cancerous diseases; biomedical research services; biological research; research relating to biotechnology; clinical research and medical research in the field of inflammatory diseases and diseases leading to tissue fibrosisimmunology and cancer; chemical research and analysis services including analytical services relating to medicinespharmaceutical preparations and biochemistry; research laboratorieslaboratory research in the field of chemistry; scientific and biotechnology research in the field of gene therapy; DNA screening for scientific research purposes; biological researchcell separation research services; research and development services in the field of immunohistology; scientific research in the field of genetics and genetic engineering; consultancy relating to research and development in the field of therapeutics; product custom design and development of medical technology; services for the development of methods of testingdevelopment and establishment of testing specifications and procedures in the field of biotechnology and pharmaceutical fields; conducting technical project studiestechnical research in the field of pharmaceutical studies; preparation of project analysis studiesconducting scientific study in the fields of medicine and biotechnology; technical consultancy relating to product development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; advisory services relating to scientific research; providing information about the results of clinical trials for others for pharmaceutical products
Publications
History of USPTO decisions and trademark events.
40 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/10/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
11/14/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
11/14/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/14/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/14/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/13/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/10/2024
GNRT
NON-FINAL ACTION E-MAILED
10/10/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
10/10/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/12/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/12/2024
ALIE
ASSIGNED TO LIE
09/12/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/24/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/24/2024
GNRT
NON-FINAL ACTION E-MAILED
01/24/2024
CNRT
SU - NON-FINAL ACTION - WRITTEN
01/24/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
01/24/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
01/23/2024
IUAF
USE AMENDMENT FILED
01/04/2024
EISU
TEAS STATEMENT OF USE RECEIVED
01/04/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
07/18/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/23/2023
PUBO
PUBLISHED FOR OPPOSITION
05/23/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/03/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/20/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
04/20/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/20/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
04/20/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/20/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/28/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/27/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/27/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/14/2022
GNRT
NON-FINAL ACTION E-MAILED
10/14/2022
CNRT
NON-FINAL ACTION WRITTEN
10/14/2022
DOCK
ASSIGNED TO EXAMINER
09/25/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
09/07/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/27/2021
NWAP
NEW APPLICATION ENTERED
12/23/2021
Continuous trademark protection
Get notified about every new filing that threatens MOLECURE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.